Welcome to our dedicated page for NEOGENOMICS SEC filings (Ticker: NEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeoGenomics, Inc. filings document the regulatory record of an oncology diagnostics company whose common stock trades on Nasdaq under the symbol NEO. Form 8-K reports furnish quarterly and annual operating results, preliminary financial information, press release exhibits, and Regulation FD disclosures tied to the company’s clinical testing and diagnostic services business.
The company’s proxy materials cover board structure, director matters, executive compensation, equity awards, pay-versus-performance disclosures and annual meeting governance. Other material-event filings describe officer transitions, board appointments and resignations, and registered security information, including common stock par value and exchange listing details.
NEOGENOMICS INC director Marjorie C. Green reported equity compensation activity and an option-related share issuance. She exercised previously reported restricted stock units into 22,964 shares of common stock, which she now holds directly. She also received new awards of 15,970 restricted stock units scheduled to vest on June 1, 2027 and 11,069 stock options exercisable at $10.52 per share expiring on June 1, 2036. A separate option position covering 16,019 underlying shares at an exercise price of $6.95 per share remains outstanding and expires on June 19, 2035. The filing shows only grants and exercises, with no open‑market purchases or sales.
NeoGenomics, Inc. reported results of its annual stockholder meeting. Stockholders approved a second amendment to the 2023 Equity Incentive Plan, increasing the shares authorized for issuance under the plan by 5,000,000 shares.
A total of 116,630,120 shares were present or represented by proxy, representing approximately 89.61% of outstanding voting stock as of March 23, 2026, ensuring a strong quorum. All nine director nominees were elected. Stockholders gave majority advisory approval to compensation for the Named Executive Officers, approved the incentive plan amendment, and ratified the appointment of Deloitte & Touche LLP as independent registered public accountant.
NEOGENOMICS, INC. reports amended beneficial ownership by Greenhouse Funds LLLP, Greenhouse GP LLC and Joseph Milano as joint filers. Each reporting person is shown with 9,215,903 shares of Common Stock, representing 7.1% of the class. The filing lists 8,318,358 shares with shared voting power and 9,215,903 shares with shared dispositive power.
The report states the shares are owned by advisory clients of Greenhouse Funds LLLP and includes a joint filing agreement and a control-person identification exhibit. Signatures by Joseph Milano dated 05/15/2026 appear on the amendment.
NeoGenomics, Inc. filing amends a prior Schedule 13G to report that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each disclose shared voting and shared dispositive power over 2,222,757 shares of NeoGenomics common stock, representing 1.7% of the class. The filing is accompanied by a Joint Filing Agreement dated May 12, 2026 and clarifies that the shares are held by entities over which the filing parties have voting or investment discretion.
NeoGenomics, Inc. executive Alicia C. Olivo, EVP, GC & Business Development, reported equity award activity on May 11, 2026. She converted 3,944 restricted stock units into an equal number of common shares, and 2,559 common shares were disposed of under code F to satisfy exercise price or tax obligations. She continues to hold multiple stock option, restricted stock unit and performance stock unit awards, including options on 107,450 shares at $13.05 expiring in 2035 and 147,804 shares at $10.81 expiring in 2036.
NeoGenomics Inc. President & Chief Operating Officer Warren Stone reported a routine equity compensation event. On May 11, 2026, he exercised 5,830 restricted stock units into an equal number of shares of common stock. Of these, 3,783 shares of common stock were withheld to satisfy tax obligations through a share delivery mechanism.
Following these transactions, Mr. Stone directly holds 164,032 shares of NeoGenomics common stock. The filing also lists substantial existing awards of restricted stock units, performance stock units, and stock options with various vesting schedules and premium exercise prices, reflecting a compensation package tied to service, share-price growth and revenue growth goals.
Neogenomics, Inc. amendment filing reports that First Light Asset Management, LLC beneficially owns 13,631,016 shares (10.47%) and Mathew P. Arens beneficially owns 14,093,416 shares (10.82%). The filing is a joint Schedule 13G/A stating shared voting and dispositive power for the Manager and Mr. Arens.
NeoGenomics Chief Accounting Officer Greg D. Aunan reported routine equity compensation activity involving restricted stock units and related tax withholding. On May 2, 2026, he exercised 5,372 restricted stock units into common stock and, in connection with vesting, surrendered shares to the company to satisfy tax obligations. The filings show 2,246 common shares disposed through issuer withholding across May 1 and May 2, 2026, and he now directly holds 25,153 shares of common stock. He also retains multiple unexercised stock option and RSU awards with exercise prices between $9.83 and $14.62 per share and expirations extending to 2036.
NeoGenomics EVP, GC & Business Development Alicia C. Olivo reported updated equity holdings in the company. The filing shows a disposition of 1,042 shares of common stock on May 1, 2026 as a tax-withholding transaction, leaving her with 92,182 common shares held directly.
Alongside these shares, she holds a range of equity awards in the form of restricted stock units, performance stock units and stock options tied to NeoGenomics common stock, with various exercise prices and expiration dates, reflecting a substantial, long-term incentive position rather than open-market trading activity.
NeoGenomics, Inc. President & Chief Operating Officer Warren Stone reported routine equity compensation activity involving restricted stock units and stock options. On May 2, 2026, he exercised awards to acquire 5,969 shares of common stock, with 2,349 shares withheld by the company to cover tax obligations related to the RSU release.
Following these transactions, Stone holds 161,985 shares of common stock directly, along with a substantial remaining equity incentive position, including 253,378 stock options at an exercise price of $10.81 and 166,113 stock options at $11.21, plus significant restricted and performance stock units that vest over future years.